Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Leases (2019 - 2025)

Myriad Genetics (MYGN) has disclosed Current Leases for 7 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 46.09% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, down 46.09% year-over-year, with the annual reading at $6.9 million for FY2025, 46.09% down from the prior year.
  • Current Leases for Q4 2025 was $6.9 million at Myriad Genetics, down from $7.9 million in the prior quarter.
  • The five-year high for Current Leases was $17.8 million in Q3 2023, with the low at $6.9 million in Q4 2025.
  • Average Current Leases over 5 years is $13.1 million, with a median of $13.4 million recorded in 2022.
  • The sharpest move saw Current Leases rose 27.82% in 2023, then plummeted 46.09% in 2025.
  • Over 5 years, Current Leases stood at $13.0 million in 2021, then rose by 8.46% to $14.1 million in 2022, then grew by 14.89% to $16.2 million in 2023, then fell by 20.99% to $12.8 million in 2024, then tumbled by 46.09% to $6.9 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $6.9 million, $7.9 million, and $9.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.